• Documents
  • Authors
  • Tables
  • Log in
  • Sign up
  • MetaCart
  • DMCA
  • Donate

CiteSeerX logo

Advanced Search Include Citations
Advanced Search Include Citations

Ten Years and Counting: Moving Leucine-Rich Repeat Kinase 2 Inhibitors to the Clinic

by PhD Andrew B West
Add To MetaCart

Tools

Sorted by:
Results 1 - 1 of 1

LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis

by Mattia Volta , Heather Melrose
"... Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of familial Parkinson's disease (PD), resembling the sporadic disorder. Intensive effort has been directed toward LRRK2 mouse modeling and investigation, aimed at reproducing the human disease to inform mechani ..."
Abstract - Add to MetaCart
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of familial Parkinson's disease (PD), resembling the sporadic disorder. Intensive effort has been directed toward LRRK2 mouse modeling and investigation, aimed at reproducing the human disease to inform mechanistic studies of pathogenesis and design of neuroprotective therapies. The physiological function of LRRK2 is still under exploration, but a clear role in striatal neurophysiology and animal behavior has emerged. Alterations in LRRK2 impair dopamine (DA) transmission, regulation and signaling, in addition to corticostriatal synaptic plasticity. Consistently, several subtle abnormalities in motor and nonmotor abilities have been demonstrated in LRRK2 genetic mouse models, generally paralleling preclinical symptoms of early DA dysfunction. However, the variability in model design and phenotypes observed requires a critical approach in interpreting the results, adapting the model used to the specific research question. Etiologically appropriate knockin mice might represent the ultimate animal model in which to study early disease mechanisms and therapies as well as to investigate drug effectiveness and off-target consequences.
(Show Context)

Citation Context

...r up to 40% of PD patients in specific populations [10,11], with ethnicity and age affecting penetrance [12]. This mutation resides in the kinase domain, and it has been shown to increase its activity, which Version of Record published: 15 February 2017 Received: 10 August 2016 Revised: 21 October 2016 Accepted: 25 October 2016 © 2017 The Author(s); published by Portland Press Limited on behalf of the Biochemical Society 113 Biochemical Society Transactions (2017) 45 113–122 DOI: 10.1042/BST20160238 prompted the development of selective LRRK2 kinase inhibitors as a disease-modifying treatment [13]. To gain insights into disease-causing mechanisms and to test molecules targeting LRRK2, several rodent models have been developed and aimed at reproducing the progressive behavioral impairments and neurodegeneration. In this review, we discuss the key features of mouse models with a focus on the role of LRRK2 on neurotransmission and neurotransmitter release in the striatum, a brain area that is critically involved in pathogenesis and symptom manifestation, and how the results from different genetic approaches could inform on the mechanisms underlying pathogenesis and aid therapeutic testing...

Powered by: Apache Solr
  • About CiteSeerX
  • Submit and Index Documents
  • Privacy Policy
  • Help
  • Data
  • Source
  • Contact Us

Developed at and hosted by The College of Information Sciences and Technology

© 2007-2019 The Pennsylvania State University